— Mallinckrodt plc (NYSE: MNK) reported fourth-quarter 2019 earnings of $2.40 per share, vs. $2.05 per share expected.
— Q4 net sales fell 3.6% to $804.9 million, vs. $772.5 million expected. The topline was helped by strong performance across hospital products and the Specialty Generics segment.
— Company says it has reached an agreement for a global settlement with a broad-based group of plaintiffs that would resolve all opioid-related claims. It would also take actions to address near-term maturities to strengthen capital structure.
— MNK shares jumped over 20% immediately following the announcement.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
